Eli Lilly, an American pharmaceutical company headquartered in Indianapolis, completed the acquisition of POINT Biopharma, a radiopharmaceutical company, for $1.4bn. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT. We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we create this new capability within Lilly. In time, I hope we can bring several new radioligand therapies to patients with cancer and improve their outcomes," Jacob Van Naarden, Eli Lilly Executive Vice President.